MAPS Changes Direction & P. Ingeli Overtakes P. Cubensis
This week’s human-and-fungal power shift comes as MAPS goes advocacy-first under new co-leaders and Psilocybe ingeli outperforms Psilocybe cubensis on everything from cultivation to potency.
They got the power! This week is about who sets the norms. Germany’s new model is pulling purchases into daylight, with a survey finding 88.6% of users now sourcing legally, while in the U.S. the Justice Department withdrew pending rules on cannabis research and hemp testing, a House panel moved to block rescheduling, and California advanced tax relief for a strained industry. In the marketplace, big drugmakers are scouting late-stage psychedelic assets; MAPS named Betty Aldworth and Ismail Lourido Ali co-executive directors as it leans into partnerships and advocacy; MJBizCon turned floor traffic into new tie-ups. Science and society are drawing the boundaries: a structured review links adolescent MDMA use with cognitive and emotional risks; UNESCO’s Mondiacult will give cannabis a global cultural hearing; seniors’ use is rising in France and across the U.S.; and on the fungal front, DoubleBlind profiles Psilocybe ingeli fast to cultivate with early community assays around 2.3–3.2% total tryptamines, pending independent lab confirmation.
Regulatory
Germany shifts purchases of cannabis into the legal light
Survey data finds most consumers now sourcing through lawful channels after the new model took hold.
Justice Department scraps pending rules on research and labs
The withdrawal resets timelines for oversight of cannabis studies and hemp testing programs.
California nudges toward relief for a tired sector
Lawmakers advanced a measure meant to ease costs as operators face slow growth and thin margins.
House panel votes to box out a cannabis rescheduling push
A rider would block a White House move and add tougher penalties near schools and parks.
Market
Big drugmakers lean in to the psychedelic pipeline
Strategy teams are scouting late-stage assets as timelines firm and safety packages mature.
MAPS installs a new co-executive duo
Betty Aldworth and Ismail Lourido Ali step in together as the nonprofit resets for its next phase.
Vegas show floor becomes a cannabis deal table
Brands and suppliers test messages under strict packaging rules and strike partnerships on-site.
Buenos Aires hosts a cross-border cannabis forum
A B2B summit brings operators and regulators together to map opportunities across the region.
Scientific
Egypt’s hidden chapter in psychedelic psychiatry resurfaces
Historians trace mid-century clinic work that widens the field’s origin story beyond the usual map.
What adolescent MDMA use may leave behind
A structured review gathers human studies and flags cognitive and emotional risks that call for clear harm reduction.
Psilocybe ingeli emerges as a fast-growing, potentially high-potency species
South African magic mushrooms are drawing buzz for their quick cultivation and early community assays, which estimate 2.3–3.2% total tryptamines, often exceeding those of P. cubensis.
Social trends
A workplace drug test ignites a national argument
A high-profile case tied to Japan sparks wider debate over privacy policy and public perception.
UNESCO places cannabis on the cultural stage
The global forum gives the plant a seat in conversations that shape heritage education and law.
France maps a rise in senior use
Reporters find a growing cohort of older consumers and the social shifts that follow in care and community.
More older Americans reach for cannabis
Pain sleep and curiosity drive adoption as stigma falls and state rules open doors.